2 No-Brainer Biotech Stocks to Buy Right Now
Following the market's gloomy 2022, this year has been a breath of fresh air with the S 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic fibrosis specialist Vertex Pharmaceuticals (NASDAQ: VRTX) has risen 19% in 2023, while cancer specialist (NASDAQ: EXEL) has gained 31% -- and both medical areas are likely to see strong demand for a long time to come.
Let's see why these two stocks could make good additions to investors' portfolios now.
Image source: Getty Images.
Source Fool.com
Exelixis Inc. Aktie
21,62 €
0,70 %
Einseitige Zustimmung für Exelixis Inc. mit mehreren Buy- und keiner Sell-Einschätzung.
Das Kursziel von 26 € für Exelixis Inc. bedeutet eine deutliche Steigerung von über 20% gegenüber dem aktuellen Kurs von 21.62 €.
